8.23

4.31% 0.34

Pre-market: 8.18 -0.05 -0.61%

Ginkgo Bioworks Holdings Inc (DNA)

Overview News Price History Option Chain Why DNA Down? Discussions Forecast

Ginkgo Bioworks Holdings Inc stock is traded at $8.23, with a volume of 637.60K. It is up +4.31% in the last 24 hours and up +6.74% over the past month. Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.

Previous Close:

$7.89

Open:

$8.215

24h Volume:

637.60K

Relative Volume:

0.51

Market Cap:

$537.62M

Revenue:

$141.31M

Net Income/Loss:

$-297.87M

P/E Ratio:

-1.526

EPS:

-5.3933

Net Cash Flow:

$-168.20M

1W Performance:

+1.73%

1M Performance:

+6.74%

6M Performance:

-5.07%

1Y Performance:

-7.94%

1-Day Range:

$8.10

$8.45

1-Week Range:

$7.63

$8.75

52-Week Range:

$5.37

$17.58

Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile

Name

Ginkgo Bioworks Holdings Inc

Sector

Healthcare (1104)

Industry

Biotechnology (621)

Phone

(877) 442-5362

Address

27 DRYDOCK AVENUE, BOSTON

Employee

485

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

DNA's Discussions on Twitter

Compare DNA vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DNA Ginkgo Bioworks Holdings Inc	8.23	537.62M	141.31M	-297.87M	-168.20M	-5.3933
VRTX Vertex Pharmaceuticals Inc	450.46	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.98	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	884.20	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	287.80	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	160.06	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-15-24	Downgrade	BTIG Research	Neutral → Sell
May-10-24	Downgrade	William Blair	Mkt Perform → Underperform
Nov-14-23	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-09-23	Downgrade	BTIG Research	Buy → Neutral
Jun-02-23	Downgrade	Goldman	Neutral → Sell
May-11-23	Downgrade	William Blair	Outperform → Mkt Perform
Nov-29-22	Initiated	Berenberg	Buy
Oct-04-22	Initiated	Morgan Stanley	Equal-Weight
May-18-22	Downgrade	BofA Securities	Neutral → Underperform
Mar-02-22	Resumed	Cowen	Outperform
Feb-23-22	Initiated	Goldman	Neutral
Feb-01-22	Initiated	BofA Securities	Neutral
Jan-28-22	Initiated	BofA Securities	Buy
Jan-07-22	Initiated	BTIG Research	Buy
Nov-29-21	Initiated	Jefferies	Buy
Oct-13-21	Initiated	Raymond James	Outperform
Oct-12-21	Initiated	William Blair	Outperform
Sep-20-21	Initiated	HSBC Securities	Buy

View All

Ginkgo Bioworks Holdings Inc Stock (DNA) Latest News

Jun 15, 2026

Ginkgo Bioworks (DNA) director Henry Christian O receives 25,000 RSU equity grant - Stock Titan

Jun 15, 2026

Director Ross Fubini receives 25,000 RSUs at Ginkgo Bioworks (NYSE: DNA) - Stock Titan

Jun 15, 2026

Director at Ginkgo Bioworks (NYSE: DNA) granted 25,000 RSUs - Stock Titan

Jun 15, 2026

Ginkgo Bioworks (DNA) director Harry Sloan awarded 25,000 RSUs - Stock Titan

Jun 15, 2026

Jun 13, 2026

Ginkgo Bioworks Holdings, Inc. Files Form 8-K With SEC for June 2026 – Key Submission Details and Company Information 17 – Minichart - Minichart

Jun 13, 2026

Jun 12, 2026

Ginkgo Bioworks (NYSE: DNA) shareholders approve directors, Deloitte and executive pay - Stock Titan

Jun 12, 2026

Ginkgo Bioworks (DNA) Short Interest & Short Float | Updated Jun 2026 $DNA - MarketBeat

Jun 12, 2026

Jun 10, 2026

Austin Che (DNA) files Form 144 showing sales totaling tens of thousands of Class A shares - Stock Titan

Jun 10, 2026

Jun 09, 2026

Precision Trading with Ginkgo Bioworks Holdings Inc. Class A (DNA) Risk Zones - Stock Traders Daily

Jun 09, 2026

Jun 07, 2026

Ginkgo Bioworks Holdings, Inc. - MLQ.ai

Jun 07, 2026

Jun 05, 2026

Top Ginkgo Bioworks (DNA) Competitors 2026 - MarketBeat

Jun 05, 2026

Jun 02, 2026

Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Ginkgo Bioworks Holdings, Inc. of Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Significant Losses to Contact the Firm - TMX Newsfile

Jun 02, 2026

May 29, 2026

Technical Reactions to DNA Trends in Macro Strategies - Stock Traders Daily

May 29, 2026

May 26, 2026

Ginkgo Bioworks (NYSE: DNA) insider logs RSU vesting and small tax-related share sale - Stock Titan

May 26, 2026

Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery - Investing News Network

May 26, 2026

Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery - marketscreener.com

May 26, 2026

Ginkgo Bioworks, Tangible Scientific, And Inductive Bio Launch ADME-One High-Throughput ADME Platform - marketscreener.com

May 26, 2026

New AI lab service aims for fewer dead ends in drug discovery - Stock Titan

May 26, 2026

May 24, 2026